1CP
BMY icon

1015 Capital Partners’s Bristol-Myers Squibb BMY Stock Holding History

1015 Capital Partners’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.1K Hold
418
– – 0.02% 172
2026
Q1 		$25.4K Sell
418
-2
-0.5% -$117 0.02% 170
2025
Q4 		$22.7K Buy
+420
New +$20.2K 0.02% 175

Other funds holding BMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

1015 Capital Partners's BMY Position: Q2 2026 in Review

1015 Capital Partners held its Bristol-Myers Squibb (BMY) position steady in Q2 2026 at 418 shares worth $24.1K. The position accounts for 0.02% of the portfolio, ranked #172.

1015 Capital Partners first reported a position in BMY in Q4 2025 and has held it in 3 quarters since. The position peaked at $25.4K in Q1 2026. 2,501 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • 1015 Capital Partners held 418 shares of Bristol-Myers Squibb worth $24.1K as of Q2 2026.
  • 1015 Capital Partners left its Bristol-Myers Squibb share count unchanged in Q2 2026.
  • Bristol-Myers Squibb made up 0.02% of 1015 Capital Partners's portfolio in Q2 2026, its #172 holding.
  • 1015 Capital Partners first reported a position in Bristol-Myers Squibb in Q4 2025 and has held it in 3 quarters since.
  • 1015 Capital Partners's Bristol-Myers Squibb position peaked at $25.4K in Q1 2026.
  • 2,501 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on 1015 Capital Partners's 13F filing for Q2 2026, filed 21 Jul 2026.